Drug approval is a long process and, let's face it, the Canadian market is small. If you are developing a drug, you are developing it for the U.S. market, the European market, and the Canadian market, because this is an economic thing. No one is going to develop a drug just for a Canadian problem. You have to sell it in every country you can in order for a drug to be successful. In doing so, one is really at the mercy of the red tape of many other countries, and the FDA can certainly define red tape for you. I think that is a difficult thing.
To follow up on a previous question, though, I think the U.S. SBIR program is a very good program. I think it's something that we should actually look at and try to emulate, because that is certainly something that facilitates the conversion of research to innovation.